PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608879
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608879
Global monkeypox (Mpox) diagnosis market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 2.62 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 1.97 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 4.20% | 2031 Value Projection: | 2.62 Bn |
Global monkeypox virus (MPXV) outbreak in 2022 highlighted the need for prompt diagnosis of the disease. Monkeypox is a rare viral zoonotic disease that is caused by infection with the Monkeypox virus. The disease presents clinically with fever, rash, and swollen lymph nodes and is usually self-limiting. However, severe cases can occur. Timely diagnosis is crucial to limit human-to-human transmission through isolation of infected patients and contact tracing.
Global monkeypox (Mpox) diagnosis market is driven by the ongoing outbreak of monkeypox cases globally. The sustained spread of monkeypox to new regions and countries where it is not usually found has prompted greater testing needs. Introduction of novel diagnostics technologies such as multiplex polymerase chain reaction tests that can detect monkeypox alongside other orthopox viruses is boosting adoption. However, low disease awareness among the public and healthcare workers in some parts of the world poses a challenge for accurate diagnosis. Increasing research activities for the development of rapid point-of-care tests provide lucrative opportunities for market players in the long run.
Key Features of the Study
This report provides in-depth analysis of the global monkeypox (Mpox) diagnosis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global monkeypox (Mpox) diagnosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Aegis Sciences Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Sonic Healthcare Limited, QIAGEN, Mayo Clinic Laboratories, Chembio Diagnostics, Inc., Sonora Quest Laboratories, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), CerTest Biotech, GenMark Diagnostics, Inc., Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Siemens Healthineers, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., and Meridian Bioscience, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global monkeypox (Mpox) diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monkeypox (Mpox) diagnosis market